Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

Steve Deitelzweiga Department of Hospital Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA;b School of Medicine, Ochsner Clinical School, The University of Queensland, New Orleans, LA, USACorrespondence[email protected]
View further author information

Gregory Y. H. Lipc Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK;d Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, DenmarkView further author information

References

Freedman B, Lip GY. “Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost. 2016;116(4):587–589.
PubMed Web of Science ®Google Scholar
Proietti M, Romanazzi I, Romiti GF, et al. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2018;49(1):98–106.
PubMed Web of Science ®Google Scholar
Deitelzweig S, Gupta K, Ogbonnaya A, et al. Compare major bleeding risk and associated costs among nvaf patients with CHA2DS2-VASC SCORE≥ 3 newly anticoagulated with apixaban versus warfarin. J Am Coll Cardiol. 2016;67(13):876.
Web of Science ®Google Scholar
Lin I, Masseria C, Mardekian J, et al. P6215: real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records. Eur Heart J. 2015;36(AbstractSupplement):1084.
Google Scholar
Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6).
Web of Science ®Google Scholar
Lamberts M, Harboe L, Lefevre C, et al. Comparison of bleeding and treatment persistence among new users of novel oral anticoagulants and warfarin in patients with non-valvular atrial fibrillation. J Am Coll Cardiol. 2016;67(13):887.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date